Compare SLGL & JRVR Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
| Metric | SLGL | JRVR |
|---|---|---|
| Founded | 1997 | 2002 |
| Country | Israel | United States |
| Employees | N/A | N/A |
| Industry | Biotechnology: Pharmaceutical Preparations | Property-Casualty Insurers |
| Sector | Health Care | Finance |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 240.3M | 288.2M |
| IPO Year | 2016 | 2014 |
| Metric | SLGL | JRVR |
|---|---|---|
| Price | $75.26 | $4.50 |
| Analyst Decision | Strong Buy | Hold |
| Analyst Count | 1 | 3 |
| Target Price | ★ $110.00 | $7.33 |
| AVG Volume (30 Days) | 22.9K | ★ 444.7K |
| Earning Date | 05-22-2026 | 05-04-2026 |
| Dividend Yield | N/A | ★ 0.64% |
| EPS Growth | N/A | ★ 125.82 |
| EPS | ★ N/A | N/A |
| Revenue | N/A | ★ $687,614,000.00 |
| Revenue This Year | N/A | N/A |
| Revenue Next Year | $223.84 | $1.61 |
| P/E Ratio | N/A | ★ N/A |
| Revenue Growth | ★ N/A | N/A |
| 52 Week Low | $6.96 | $3.76 |
| 52 Week High | $97.97 | $7.20 |
| Indicator | SLGL | JRVR |
|---|---|---|
| Relative Strength Index (RSI) | 52.66 | 57.96 |
| Support Level | $70.05 | $3.79 |
| Resistance Level | $75.00 | $5.48 |
| Average True Range (ATR) | 4.83 | 0.17 |
| MACD | 0.05 | 0.08 |
| Stochastic Oscillator | 46.76 | 93.62 |
Sol-Gel Technologies Ltd is a dermatology company. It is engaged in identifying, developing and commercializing branded and generic topical drug products for the treatment of skin diseases. The company's product candidate pipeline includes SGT-610 (Patidegib Gel 2%), a new chemical entity hedgehog signaling pathway blocker, for the chronic use and prevention of new BCC in Gorlin syndrome patients, and the topical drug candidate SGT-210 for the treatment of Darier Disease and other rare keratosis-related indications such as PC, PPK and Olmsted. It generates the majority of its revenue from the United States.
James River Group Holdings Inc is a holding company that owns and operates a group of specialty insurance companies focused on underwriting small and middle market casualty risks within the U.S. excess and surplus (E&S) lines market. The Company operates in two specialty property-casualty insurance segments: Excess and Surplus Lines and Specialty Admitted Insurance.